Pay in 4 interest-free payments of $5.02 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Reduced food intake must first deplete your body's stored energy (glycogen and fat) before scale weight changes noticeably
Hypoglycemia While tirzepatide and semaglutide themselves have a low risk of causing low blood sugar, the risk increases when used with other diabetes medications like insulin or sulfonylureas
Alternative GLP-1 options to consider If the Boothwyn findings concern you, exploring alternative GLP-1 compounds and delivery methods is worthwhile
Common Side Effects Reported Across Phase 2 trials, participants experienced dose-dependent GI symptoms that are characteristic of GLP-1 receptor agonists: Nausea most frequent, especially during dose escalation Vomiting typically mild to moderate, subsiding with continued use Diarrhea and constipation fluctuating depending on individual tolerance Abdominal discomfort transient and often improved over time Dose-Response Relationship At lower doses (14 mg weekly), side effects were generally mild and manageable, though some participants still reported early GI symptoms
Affiliation: B
A clinical trial studies a drug under strict research rules
